title: [Clinical study of photodynamic therapy with visudyne for polypoidal choroidal vasculopathy].
abstract: OBJECTIVE
  To study the clinical effect of photodynamic therapy (PDT) with Visudyne for polypoidal choroidal vasculopathy (PCV).
  
  
  METHODS
  Ten patients (10 eyes) with PCV who were diagnosed by fundus fluorescein angiography (FFA), indocyanine green angiography (ICGA), optic coherence tomography (OCT) were treated by PDT with Visudyne. Eight cases (8 eyes) were male, the other two cases (2 eyes) were female. Their ages ranged from 50 to 77 years, mean (59.5 +/- 9.70) years. The best corrected visual activity (BCVA) before PDT was 0.1 - 0.5. The changes of BCVA, fundus photography, FFA and ICGA before and after PDT were compared. Follow-up time varied from 6 months to 36 months, mean 24 months.
  
  
  RESULTS
  1 month after PDT the BCVA was found to be unchanged in 4 eyes, increased in 1 line in 3 eyes, increased in 2 lines in 2 eyes, decreased in 3 lines in 1 eye. FFA and/or ICGA showed no leakage in 4 eyes, leakage reduced in 3 eyes, slight leakage in 2 eyes. At the last follow-up, the BCVA was found to be unchanged in 4 eyes, increased in 1 line in 2 eyes, increased in 2 lines in 2 eyes, increased in 3 lines in 1 eye which received 3 times PDT, decreased in 2 lines in 1 eye. FFA/ICGA showed no leakage in 7 eyes, slight leakage in 2 eyes. No systemic or local adverse effect was found during or after PDT, except 1 eye with extensive subretinal hemorrhage suffered vitreous hemorrhage one month after PDT.
  
  
  CONCLUSIONS
  Photodynamic therapy with Visudyne may stop or reduce the macular leakage, facilitate the absorption of hemorrhage, exudates and edema, stabilize or increase the patients' visual activities. It could be a choice for the treatment of PCV. Certainly these tendencies need to be confirmed in a multi-center randomized controlled investigation with longer follow-up time.
authors: Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510060, China. zoclcjjin@yahoo.com
authors: Chen-jin
authors: CJ
authors: Jin
authors: Yan
authors: Y
authors: Zhang
authors: Zhen
authors: Z
authors: Tian
authors: Ning
authors: N
authors: Kong
authors: Xiao-jing
authors: XJ
authors: Zhong
authors: Shao-bo
authors: SB
authors: Zhou
authors: Feng
authors: F
authors: Wen
authors: Hong
authors: H
authors: Yan
authors: Shi-bo
authors: SB
authors: Tang
authors: Jian
authors: J
authors: Ge
mesh_terms: D000368:Aged; D015862:Choroid Diseases / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D016896:Treatment Outcome; D000077362:Verteporfin
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin